文献速递乳腺MR

乳腺MRI背景实质强化作为分子癌亚型的影像学桥梁

Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
PubMed 文献 · Eur J Radiol · 2019-02-15

回顾性分析82例乳腺癌患者的乳腺DCE-MRI,评估背景实质强化(BPE)在不同分子亚型间的分布差异。轻度BPE在Luminal B(HER2-)肿瘤中更常见(p=0.0001),显著BPE在三阴性肿瘤中更常见(p=0.0074)。作者认为BPE可能作为分子亚型的影像学桥梁,但需更大样本研究证实。

要点

  • 轻度BPE患者中Luminal B(HER2-)肿瘤比例显著更高(p=0.0001)。
  • 显著BPE患者中三阴性亚型比例显著更高(p=0.0074)。
  • BPE定性评估观察者间一致性几乎完美(Cohen's k=0.83)。

核心结论

  • BPE可能作为分子乳腺癌亚型的影像学桥梁,在乳腺MRI领域及靶向筛查中提供额外的风险分层。
  • CE-MRI上轻度BPE时Luminal B(HER2-)肿瘤可能更常见,显著BPE患者中三阴性肿瘤可能更常见。
  • 作者指出需更大样本的进一步研究证实该假设。

研究设计与样本

  • 回顾性研究,纳入82例连续乳腺癌患者,均行乳腺DCE-MRI。
  • 两名放射科医生回顾性评估所有减影MR增强图像以分类BPE。
  • ER、PR状态采用Allred评分(阳性值:评分≥3),cerbB-2染色强度评分为0、1+、2+或3+(阳性值:≥3+;阴性:0和1+;2+值采用银原位杂交评估)。
  • 患者按癌症亚型分为五类:Luminal A、Luminal B HER2阴性、Luminal B HER2阳性、HER2阳性非Luminal、三阴性。
  • 采用χ2检验评估BPE类型在五组肿瘤亚型中的分布显著性及五种乳腺癌亚型在每种BPE类型中的分布;采用多因素回归分析和逻辑回归研究BPE与年龄、绝经状态和病灶直径等因素的相关性;采用Cohen's kappa统计评估BPE分类的观察者间一致性。

诊断标准与关键数值

  • 82例中Luminal A样6/82(7.3%),Luminal B样(HER2-)42/82(51.2%),Luminal B样(HER2+)12/82(14.6%),非Luminal(HER+)4/82(4.9%),三阴性(导管)18/82(22%)。
  • 82例中极小BPE 16/82,轻度BPE 28/82,中度BPE 22/82,显著BPE 16/82。
  • 轻度BPE模式仅在Luminal B(HER-)肿瘤中显著更常见(p=0.0001)。
  • 三阴性肿瘤中中度和显著BPE超过极小和轻度BPE。
  • 所有轻度BPE患者中Luminal B(HER2-)肿瘤显著更高(p=0.0001);所有显著BPE患者中三阴性亚型显著更高(p=0.0074)。

临床应用与阅片要点

  • 在乳腺CE-MRI检查中,轻度BPE可能与Luminal B(HER2-)肿瘤更常见相关,显著BPE可能与三阴性肿瘤更常见相关,作者认为BPE可能作为分子亚型的影像学桥梁用于风险分层。

局限性

  • 作者指出需更大样本的进一步研究证实该假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the distribution of MRI breast parenchymal enhancement (BPE) among different breast cancer subtypes searching for any significant difference in terms of immunohistochemical and receptorial patterns (Estrogen Receptor -ER, Progesterone Receptor - PR, Human Epidermal Growth Factor Receptor 2 - HER2).

METHODS: 82 consecutive patients affected by breast cancer underwent breast DCE-MRI. Two radiologists retrospectively evaluated all subtracted MR enhanced images for classifying BPE. ER, PR and HER2 expression was assessed by immunohistochemical analysis. ER and PR status was evaluated using Allred score (positive values: score ≥3). The intensity of the cerbB-2 staining was scored as 0, 1+, 2+, or 3+ (positive values: ≥ 3+; negative:0 and 1+; 2+ value assessed with silver in-situ hybridization). Patients were classified into five categories based on cancer subtypes: Luminal A, Luminal B HER2 negative, Luminal B HER2 positive, HER2 positive non luminal, triple negative. The χ2 test was used for evaluating the significance of BPE type distribution into the five groups of tumor subtypes and the distribution of the five breast cancer subtypes among every single BPE type. The correlation of BPE with factors such as age, menopausal status and lesion diameter was investigated using multivariate regression analysis and logistic regression. Cohen's kappa statistics was used in order to assess inter-observer agreement for classifying BPE.

RESULTS: 6/82 cases were Luminal A-like (7.3%), 42/82 Luminal B-like (HER2-) (51.2%), 12/82 Luminal B-like (HER2+) (14.6%), 4/82 Non Luminal (HER+) (4.9%), 18/82 Triple Negative (ductal) (22%). 16/82 cases showed minimal BPE, 28/82 mild BPE, 22/82 moderate BPE, 16/82 marked BPE. Mild BPE pattern was significantly more prevalent (p = 0.0001) than other BPE types only in the luminal B (HER-) tumors. Moderate and marked BPE prevailed over minimal and mild, in triple negatives. Among all patients with mild BPE, luminal B (HER2-) tumors were significantly higher (p = 0.0001). Among all patients with marked BPE, triple negative subtypes were significantly higher (p = 0.0074). No significant confounder to BPE qualitative evaluation was found (p = 0.39). The inter-rater agreement in evaluating BPE patterns on MRI was almost perfect with Cohen's k = 0.83.

CONCLUSIONS: BPE could play a crucial role as an imaging bridge to molecular breast cancer subtype allowing an additional risk stratification in the field of breast MRI and targeted screening tests. Luminal B (HER2-) tumors could prevail in case of mild BPE on CE-MRI examinations and TN tumors in patients with marked BPE. Further studies on larger series are needed to confirm this hypothesis.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Dilorenzo G, Telegrafo M, La Forgia D, et al. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type. Eur J Radiol. 2019. PMID: 30927939. doi:10.1016/j.ejrad.2019.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。